Solid Tumor Targeting CAR-T Development Service: Dominant-Negative Receptor

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides a comprehensive Dominant-Negative Receptor (DNR)–based CAR-T development service designed to overcome T-cell exhaustion and suppressive signaling in solid tumors. We engineer CAR-T cells with customized DNR constructs to block inhibitory pathways such as TGF-β, PD-1, or Fas, enabling enhanced persistence, sustained cytotoxicity, and resistance to the hostile tumor microenvironment. Our platform includes DNR design, vector construction, stable expression, functional validation, and preclinical assessment to help you generate next-generation CAR-T candidates with superior anti-tumor performance.

Introduction

CAR-T cell therapy has revolutionized oncology, yet its efficacy against solid tumors remains significantly limited by the immunosuppressive tumor microenvironment (TME). A primary inhibitor is Transforming Growth Factor β (TGF-β), which is actively secreted by many aggressive solid cancers, including prostate cancer, to paralyze the immune response. Creative Biolabs offers advanced T-cell engineering to counteract this threat by co-expressing the CAR with a dominant-negative TGF-β Receptor II (dnTGF-BRII). This molecular shield prevents T-cell exhaustion and promotes superior T-cell persistence and proliferation.

The current state and distribution of DNR-CAR-T cell therapy in cancer research. (OA Literature)
Fig.1 The landscape of DNR-CAR-T cell therapy in cancer research.¹

Service

Creative Biolabs offers an end-to-end DNR- based CAR-T engineering service, specifically designed to overcome TGF–β–mediated immunosuppression in solid tumors. We design and construct customized DNR modules that effectively block inhibitory signaling, followed by seamless integration into your CAR-T architecture. Our service includes vector development, stable cell engineering, functional validation of resistance to TGF-β–rich environments, cytotoxicity and persistence assays, and in vivo evaluation upon request. Through this platform, we deliver robust, genetically shielded CAR-T candidates optimized for enhanced proliferation, durable activity, and readiness for advanced preclinical.

Discover How We Can Help - Request a Consultation.

Our Components

Technology Components of Dominant-Negative Receptor CAR-T Development. (Creative Biolabs Original)

Workflow: Precision Engineering and Validation

Creative Biolabs' robust, modular workflow is designed for seamless translation of advanced receptor designs into clinical-grade CAR T-cell candidates. This process is structured for maximum clarity and efficiency. The required starting materials include target antigen information with amino acid and nucleotide sequences, vector backbone details including the desired system and co-stimulatory domains, and T-cell source material such as leukapheresis-derived PBMC or enriched T-cells.

Workflow of Dominant-Negative Receptor CAR-T Development. (Creative Biolabs Original)

Why Choose Us

Immunosuppressive Pathway Resistance: We engineer CAR-T cells to maintain function in TGF-β/IL-10-rich TMEs using validated DNR modules, enhancing proliferation, cytotoxicity, and persistence without altering antigen specificity.
Integrated Vector Design: Tailored co-expression via 2A peptides, dual promoters, or conditional systems ensures optimal CAR/DNR balance for tumor-specific activity and safety.
Functional Validation in Suppressive TME: Rigorous testing under TGF-β challenge confirms sustained proliferation, cytokine secretion, tumor killing, and minimal exhaustion.

FAQs

How does a Dominant-Negative Receptor improve CAR-T performance in solid tumors?

A DNR blocks specific suppressive pathways, most notably TGF-β signaling, by binding to the ligand without transmitting downstream inhibitory signals. CAR-T cells maintain proliferation, cytotoxicity, and cytokine production despite high levels of TGF-β. This approach is particularly effective for tumors with immunosuppressive microenvironments.

Can DNR modules be combined with additional CAR-T enhancements?

Yes. DNR structures integrate well with chemokine receptor engineering, cytokine-armoring, and checkpoint-pathway modifications. The combination can produce synergistic improvements in infiltration and functional durability. Creative Biolabs supports multi-module CAR-T designs to help clients achieve maximal solid tumor efficacy.

Are there safety considerations when using DNR-engineered CAR-T cells?

Although DNRs reduce inhibitory signaling, they can influence normal T-cell homeostasis depending on expression levels and construct architecture. Creative Biolabs carefully modulates expression strength and performs targeted functional testing to ensure balanced activation without excessive systemic risk.

Partner with Us

Creative Biolabs delivers end-to-end support for projects leveraging Dominant-Negative Receptors to enhance CAR-T cell performance in suppressive solid tumor microenvironments. Services include construct design, co-expression optimization, in vitro suppression-resistance assays, and in vivo validation using representative tumor models. Clients receive tailored strategies designed to accelerate development and improve translational potential. Creative Biolabs welcomes inquiries from teams planning advanced solid tumor CAR-T projects. For project-specific feasibility analysis, contact us for a tailored assessment.

Reference

Tian, Yonggui et al. “Gene modification strategies for next-generation CAR T cells against solid cancers.” Journal of hematology & oncology vol. 13,1 54. 18 May. 2020. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s13045-020-00890-6

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.